c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
128 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
(R)-Afatinib
CAS :<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Formule :C24H25ClFN5O3Couleur et forme :SolidMasse moléculaire :485.94Vabametkib
CAS :<p>Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.</p>Formule :C29H34N12OCouleur et forme :SolidMasse moléculaire :566.66SOMG-833 HCl
CAS :<p>SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.</p>Formule :C22H22F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :445.44met-kinase-in-2
CAS :<p>MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.</p>Formule :C33H27FN4O4Couleur et forme :SolidMasse moléculaire :562.59Entacapone acid
CAS :<p>Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).</p>Formule :C10H6N2O6Degré de pureté :98.86%Couleur et forme :SolidMasse moléculaire :250.16SOMCL-863
CAS :<p>SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo.</p>Formule :C23H24F3N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :475.46BPI-9016M
CAS :<p>BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.</p>Formule :C25H18F2N4O3Couleur et forme :SolidMasse moléculaire :460.43Terevalefim
CAS :<p>Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.</p>Formule :C9H8N2SDegré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :176.24c-met-IN-1
CAS :<p>c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.</p>Formule :C35H37FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.7OSI-296
CAS :<p>OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.</p>Formule :C21H19Cl2FN4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.3MET kinase-IN-3
CAS :<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Formule :C25H16ClF2N5O2Couleur et forme :SolidMasse moléculaire :491.88Adrixetinib
CAS :<p>Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity .</p>Formule :C25H24F3N5O5Couleur et forme :SolidMasse moléculaire :531.48Emzeltrectinib
CAS :<p>Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formule :C17H15F3N6OCouleur et forme :SolidMasse moléculaire :376.34Resencatinib
CAS :<p>Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formule :C30H29N7O3Couleur et forme :SolidMasse moléculaire :535.6Tyrosine kinase-IN-6
CAS :<p>Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].</p>Formule :C37H31F2N5O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :695.73MK-2461
CAS :<p>MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an</p>Formule :C24H25N5O5SDegré de pureté :95.41% - 99.53%Couleur et forme :SolidMasse moléculaire :495.55Zongertinib
CAS :<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Formule :C29H29N9O2Degré de pureté :98.24%Couleur et forme :SolidMasse moléculaire :535.6EGFR-IN-8
CAS :<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formule :C32H23ClF3N7O4Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :662.02c-Met-IN-2
CAS :<p>c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.</p>Formule :C24H21FN10ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :484.49SJF 8240
CAS :<p>c-MET degrader with foretinib linked to VHL ligand; reduces c-MET in 6h, hampers AKT, halts GTL16 cells (IC50=66.7nM), acts on exon-14-less c-MET.</p>Formule :C58H65F2N7O11SCouleur et forme :SolidMasse moléculaire :1106.25BMS-748730
CAS :<p>BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.</p>Formule :C22H26ClN7O3SCouleur et forme :SolidMasse moléculaire :504.01D6808
<p>D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.</p>Formule :C30H25F3N6O2Couleur et forme :SolidMasse moléculaire :558.55c-Met-IN-26
CAS :<p>c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.</p>Formule :C24H19F2N9Couleur et forme :SolidMasse moléculaire :471.46TAM&Met-IN-1
CAS :<p>TAM&Met-IN-1 inhibits AXL, MER, TYRO3 with IC50s 6.1, 13.2, 21.6 nM, respectively, for cancer research.</p>Formule :C29H27F2N7O5Couleur et forme :SolidMasse moléculaire :591.57Zurletrectinib
CAS :<p>Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.</p>Formule :C19H19F2N7O2Couleur et forme :SolidMasse moléculaire :415.4KRC-00715
CAS :<p>KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.</p>Formule :C25H25F3N8O3Couleur et forme :SolidMasse moléculaire :542.51Tyrosine kinase inhibitor
CAS :<p>Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.</p>Formule :C31H31FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.61Canlitinib
CAS :<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Formule :C33H31F2N3O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.61
